Compare PRO & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRO | PHAT |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.6M |
| IPO Year | 2007 | 2019 |
| Metric | PRO | PHAT |
|---|---|---|
| Price | $23.25 | $14.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $24.54 | $17.33 |
| AVG Volume (30 Days) | ★ 1.2M | 799.8K |
| Earning Date | 10-27-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,682,000.00 | $147,190,000.00 |
| Revenue This Year | $10.50 | $218.59 |
| Revenue Next Year | $10.86 | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.92 | ★ 460.30 |
| 52 Week Low | $13.61 | $2.21 |
| 52 Week High | $29.84 | $16.27 |
| Indicator | PRO | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 76.65 | 54.15 |
| Support Level | $23.06 | $14.12 |
| Resistance Level | $23.20 | $16.27 |
| Average True Range (ATR) | 0.05 | 0.67 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 95.24 | 28.67 |
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.